CBH Health LLC

1. Vanda Pharmaceuticals Inc. $3,856,061 55 payments
2. Allergan Inc. $3,012,349 156 payments
3. Moderna TX, Inc. $2,612,432 372 payments
4. Otsuka Pharmaceutical Development & Commercialization, Inc. $2,501,932 6 payments
5. Teva Pharmaceuticals USA, Inc. $2,248,242 167 payments
6. ITI, Inc. $2,112,498 735 payments
7. AbbVie, Inc. $1,493,463 46 payments
8. Takeda Pharmaceuticals U.S.A., Inc. $1,121,227 62 payments
9. Sumitomo Pharma America, Inc. $820,862 58 payments
10. Bavarian Nordic A/S $781,345 25 payments

1. Evaluation of Efficacy and Safety of Iloperidone in the Treatment of Bipolar I Disorder $3,117,052 23 payments
2. A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study with an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients with Schizophrenia $2,092,292 135 payments
3. Iti-007-452 $2,079,176 727 payments
4. A Trial of Multiple-doses of Aripiprazole in Adults With Schizophrenia or Bipolar 1 Disorder $1,951,178 2 payments
5. A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age $1,297,745 41 payments
6. A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses (10 mg and 30 mg QD) of?CVL-231?(Emraclidine) in Participants With Schizophrenia Experiencing an Acute Exacerbation of Psychosis $1,034,105 9 payments
7. ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 $781,345 25 payments
8. A Randomized, Double-blind, Placebo-controlled, Multicenter, Efficacy and Safety Study of Rapastinel for Rapid Treatment of Symptoms of Depression and Suicidality in Adult Patients with Major Depressive Disorder $677,678 15 payments
9. A Study to Evaluate Efficacy, Tolerability, Pharmacodynamic and Pharmacokinetics of Multiple Oral Doses of TAK-831 in Adults With Schizophrenia $514,331 14 payments
10. Double-Blind, Placebo-Controlled, Randomized Withdrawal, Multicenter Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in the Prevention of Relapse in Bipolar I Disorder Patients Whose Current Or Most Recent Episode Is Manic $481,942 15 payments

1. Other $683,964 19 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.